SE1500434A1 - A novel fusion partner for highly efficient and safe vaccines - Google Patents
A novel fusion partner for highly efficient and safe vaccines Download PDFInfo
- Publication number
- SE1500434A1 SE1500434A1 SE1500434A SE1500434A SE1500434A1 SE 1500434 A1 SE1500434 A1 SE 1500434A1 SE 1500434 A SE1500434 A SE 1500434A SE 1500434 A SE1500434 A SE 1500434A SE 1500434 A1 SE1500434 A1 SE 1500434A1
- Authority
- SE
- Sweden
- Prior art keywords
- fusion partner
- vaccine composition
- original
- composition according
- proteins
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 11
- 230000004927 fusion Effects 0.000 title claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 7
- 241000235789 Hyperoartia Species 0.000 claims abstract 4
- 241000251752 Myxine glutinosa Species 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims abstract 4
- 210000000265 leukocyte Anatomy 0.000 claims abstract 4
- 230000003449 preventive effect Effects 0.000 claims abstract 4
- 230000001225 therapeutic effect Effects 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 102000036639 antigens Human genes 0.000 claims abstract 3
- 108091007433 antigens Proteins 0.000 claims abstract 3
- 210000004899 c-terminal region Anatomy 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims 3
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 102000000795 Galectin 1 Human genes 0.000 claims 1
- 108010001498 Galectin 1 Proteins 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000009285 allergic inflammation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000001023 pro-angiogenic effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
The invention relates to the use of the C terminal region of Lamprey or Hagfish variable leukocyte receptor (VLR) as fusion partner in various vaccine antigens to be used in therapeutic or preventive vaccine formulations for the treatment of inflammatory, autoimmune conditions or cancer.
Claims (7)
1. A Vaccine composition stimulating the immune system to induce a strong therapeutic or preVentiVeantibody response against any therapeutic target self-antigen or -protein and containing the targetantigen, or a part or fragment thereof, being fused to a fusion partner, and optionally apharmaceutically acceptable adjuVant, characterized in that the fusion partner is the C terminalpentamerizing (multimerizing) region of the hagfish or lamprey Variable leukocyte receptor B (VLR-B), in its original or mutated form.
2. A Vaccine composition according to claim 1 for therapeutic or preVentiVe treatment of cancertumors, allergic inflammation, autoimmune disorders or other inflammatory conditions.
3. A Vaccine composition according to claim 1 or 2, characterized in that it is directed against self-proteins expressed in and around tumor Vessels and containing a single or a combination of the aminoacid sequences of the extra domain B of fibronectin (EDB), the extra domain A of fibronectin (EDA)or the extra domain C of tenascin C or at least one fragment thereof, in its original or multimerizedform, coupled to the fusion partner.
4. A Vaccine composition according to claim 1 or 2, characterized in that it is directed against self-proteins acting as immunosupressants in treating tumors and containing the proangiogenic andimmunosuppressiVe protein galectin-1 or at least one fragment thereof, in its original or multimerizedform, coupled to the fusion partner.
5. A Vaccine composition according to claim 1 or 2, characterized in that is directed against self-proteins acting as early regulators of inflammatory conditions and containing a single or combinationsof the cytokines IL-SS, 11-31, IL-18, IL-17 and thymic stromal lymphopoietin (TSLP) or at least onefragment thereof, in its original or multimerized form, coupled to the fusion partner.
6. A fusion partner to generate a Vaccine antigen to target Various self-proteins in a preVentiVe ortherapeutic Vaccine composition according to any of claims 1-5, characterized by being the the Cterminal pentamerizing (multimerizing) region of the hagfish or lamprey Variable leukocyte receptor B(VLR-B), in its original or mutated form.
7. The use of a fusion partner according to claim 6, being the C terminal pentamerizing(multimerizing) region of the hagfish or lamprey Variable leukocyte receptor B (VLR-B), in itsoriginal or mutated form, as a fusion partner to generate a Vaccine antigen to target Various self-proteins in a preVentiVe or therapeutic Vaccine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1500434A SE1500434A1 (en) | 2015-10-29 | 2015-10-29 | A novel fusion partner for highly efficient and safe vaccines |
| PCT/SE2016/000056 WO2017074235A1 (en) | 2015-10-29 | 2016-10-12 | A novel fusion partner for safe vaccines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1500434A SE1500434A1 (en) | 2015-10-29 | 2015-10-29 | A novel fusion partner for highly efficient and safe vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE1500434A1 true SE1500434A1 (en) | 2017-04-30 |
Family
ID=58631989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1500434A SE1500434A1 (en) | 2015-10-29 | 2015-10-29 | A novel fusion partner for highly efficient and safe vaccines |
Country Status (2)
| Country | Link |
|---|---|
| SE (1) | SE1500434A1 (en) |
| WO (1) | WO2017074235A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101972894B1 (en) * | 2017-05-18 | 2019-04-29 | 경상대학교산학협력단 | Fusion protein comprising C-terminus from lamprey VLRB protein linked to hagfish VLRB protein with deleted hydrophobic tail domain and uses thereof |
| US20220347261A1 (en) * | 2021-04-23 | 2022-11-03 | Vlp Therapeutics, Inc. | Galectin-targeting immunotherapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2049564T3 (en) * | 2006-08-02 | 2017-07-24 | Uab Res Found | METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE Lymphocyte RECEPTORS WITH DEFINED ANTIGEN SPECIFICITY |
| KR20120107741A (en) * | 2011-03-22 | 2012-10-04 | 한국생명공학연구원 | Method for screening protein therapeutics for sepsis treatment |
| WO2015168469A1 (en) * | 2014-05-02 | 2015-11-05 | Emory University | Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto |
| WO2016097369A1 (en) * | 2014-12-19 | 2016-06-23 | Sanofi Pasteur | Multimerization of recombinant protein by fusion to a sequence from lamprey |
-
2015
- 2015-10-29 SE SE1500434A patent/SE1500434A1/en not_active Application Discontinuation
-
2016
- 2016-10-12 WO PCT/SE2016/000056 patent/WO2017074235A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017074235A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010972A (en) | High affinity mage-a1-specific tcrs and uses thereof. | |
| MX2019014695A (en) | Interleukin-2 fusion proteins and uses thereof. | |
| MX2016010174A (en) | Interleukine 10 immunoconjugates. | |
| MX2018010586A (en) | Sting activating nanovaccine for immunotherapy. | |
| MX2023014569A (en) | Anti-sirp alpha antibodies. | |
| MX2021013837A (en) | Combination immunotherapy approach for treatment of cancer. | |
| PH12019502755A1 (en) | Antibodies that specifically bind pd-1 and methods of use | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| WO2015157252A8 (en) | Treatment of cancer using anti-cd19 chimeric antigen receptor | |
| MD4733C1 (en) | Anti-TIGIT antibodies | |
| PH12020500670A1 (en) | Molecular adjuvant | |
| MX2023014921A (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy. | |
| MX2011010977A (en) | Combination immunotherapy compositions against cancer and methods. | |
| SG10201903349YA (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| MX2018004598A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy. | |
| PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
| WO2004112825A3 (en) | Combinations of tumor-associated antigens for the treatment of various types of cancers | |
| WO2015136287A3 (en) | Compositions and methods relating to the treatment of diseases | |
| MX2023001540A (en) | Cancer vaccines and methods of treatment using the same. | |
| MX2020007555A (en) | Factor h potentiating antibodies and uses thereof. | |
| SA521422581B1 (en) | Antibodies Against IL-7R Alpha Subunit and uses thereof | |
| MX2021003281A (en) | Anti-human cd45rc antibodies and uses thereof. | |
| PH12019500434A1 (en) | Anti-gm-csf antibodies and uses thereof | |
| SE1500434A1 (en) | A novel fusion partner for highly efficient and safe vaccines | |
| MX2018013685A (en) | Combination prime: boost therapy. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAV | Patent application has lapsed |